Takahiro Mori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11003385/publications.pdf

Version: 2024-02-01

840776 1125743 15 446 11 13 citations h-index g-index papers 16 16 16 686 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer. Breast Cancer, 2017, 24, 336-340.	2.9	4
2	Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PLoS ONE, 2017, 12, e0176972.	2. 5	13
3	The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. PLoS ONE, 2017, 12, e0179694.	2.5	75
4	Somatic alteration and depleted nuclear expression of BAP 1 in human esophageal squamous cell carcinoma. Cancer Science, 2015, 106, 1118-1129.	3.9	20
5	Genetic Polymorphisms of Dihydropyrimidinase in a Japanese Patient with Capecitabine-Induced Toxicity. PLoS ONE, 2015, 10, e0124818.	2.5	21
6	Dihydropyrimidinase Deficiency with Severe 5-fluorouracil Toxicity Caused by Capecitabine. Japanese Journal of Gastroenterological Surgery, 2015, 48, 644-649.	0.1	0
7	Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on <i>KRAS</i> Mutation Status (T-CORE0801). Oncology, 2014, 87, 7-20.	1.9	69
8	Curative resection of gastric tube cancer by hand-assisted thoracoscopic surgery. Esophagus, 2013, 10, 123-127.	1.9	3
9	Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2013, 18, 670-677.	2.2	32
10	Regulation of PML-dependent transcriptional repression by pRB and low penetrance pRB mutants. Oncogene, 2002, 21, 5557-5565.	5.9	16
11	Cdk2-dependent Phosphorylation and Functional Inactivation of the pRB-related p130 Protein in pRB(â^'), p16INK4A(+) Tumor Cells. Journal of Biological Chemistry, 2000, 275, 30317-30325.	3.4	40
12	Analysis of the p53 gene mutations in patients with multiple primary cancers of the oesophagus. European Journal of Surgical Oncology, 1997, 23, 298-303.	1.0	15
13	Multistep Carcinogenesis of Esophageal Carcinoma. , 1997, , 15-21.		1
14	Accumulation of genetic alterations during esophageal carcinogenesis. Human Molecular Genetics, 1994, 3, 1969-1971.	2.9	38
15	Allelotype study of esophageal carcinoma. Genes Chromosomes and Cancer, 1994, 10, 177-182.	2.8	99